Asymmetric and symmetric dimethylarginine in adolescents with hyperuricemia

Disease Markers

Volumn 35, Issue 5, 2013, Pages 407-412

  Tenderenda Banasiuk, Edyta ^a   Wasilewska, Anna ^a   Taranta Janusz, Katarzyna ^a   Korzeniecka Kozerska, Agata ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

6 N N DIMETHYLARGININE; ARGININE DERIVATIVE; C REACTIVE PROTEIN; N(G),N(G) DIMETHYLARGININE; UNCLASSIFIED DRUG; URIC ACID;

ADOLESCENT; AMINO ACID BLOOD LEVEL; ARTICLE; COLORIMETRY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REFERENCE VALUE; URIC ACID BLOOD LEVEL;

ADOLESCENT; ARGININE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; HYPERURICEMIA; MALE; URIC ACID;

EID: 84890418745     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/267697     Document Type: Article

References (36)

1. J. V. Selby, G. D. Friedman, and C. P. Quesenberry Jr., "Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serumcholesterol, and other serum chemistries," American Journal of Epidemiology, vol. 131, no. 6, pp. 1017-1027, 1990.
2. R. J. Johnson, D.-H.Kang, D. Feig et al., "Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?" Hypertension, vol. 41, no. 6, pp. 1183-1190, 2003.
3. S. G. Wannamethee, "Serum uric acid is not an independent risk factor for coronary heart disease," Current Hypertension Reports, vol. 3, no. 3, pp. 190-196, 2001.
4. U. M. Khosla, S. Zharikov, J. L. Finch et al., "Hyperuricemia induces endothelial dysfunction," Kidney International, vol. 67, no. 5, pp. 1739-1742, 2005.
5. J. George and A. D. Struthers, "Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress," VascularHealth and RiskManagement, vol. 5, pp. 265-272, 2009.
6. P. Vallance, A. Leone, A. Calver, J. Collier, and S. Moncada, "Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure," The Lancet, vol. 339, no. 8793, pp. 572-575, 1992.
7. P. O. Bonetti, L. O. Lerman, and A. Lerman, "Endothelial dysfunction: a marker of atherosclerotic risk," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 168-175, 2003.
8. R. H. Böger, R.Maas, F. Schulze, and E. Schwedhelm, "Elevated levels of asymmetric dimethylarginine (ADMA) as a marker for cardiovascular disease and mortality," Clinical Chemistry and Laboratory Medicine, vol. 43, no. 10, pp. 1124-1129, 2005.
9. K. Y. Lin, A. Ito, T. Asagami et al., "Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase," Circulation, vol. 106, no. 8, pp. 987-992, 2002.
10. E. I. Closs, F. Z. Basha, A. Habermeier, and U. Förstermann, "Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B," Nitric Oxide, vol. 1, no. 1, pp. 65-73, 1997.
11. C.-M. Hwu and K.-H. Lin, "Uric acid and the development of hypertension," Medical Science Monitor, vol. 16, no. 10, pp. RA224-RA230, 2010.
12. Z. Kulaga, M. Litwin, M. Tkaczyk et al., "The height-, weight-, and BMI-for-age of Polish school-aged children and adolescents relative to international and local growth references," BMC Public Health, vol. 10, article 109, 2010.
13. M. de Onis, A. Onyango, E. Borghi, A. Siyam, M. Blssner, and C. Lutter, "Worldwide implementation of the WHO child growth standards," Public Health Nutrition, vol. 15, pp. 1603-1610, 2012.
14. C. Zoccali, R. Maio, F. Mallamaci, G. Sesti, and F. Perticone, "Uric acid and endothelial dysfunction in essential hypertension," Journal of the American Society of Nephrology, vol. 17, no. 5, pp. 1466-1471, 2006.
15. W.-J. Ho, W.-P. Tsai, K.-H. Yu et al., "Association between endothelial dysfunction and hyperuricaemia," Rheumatology, vol. 49, no. 10, pp. 1929-1934, 2010.
16. H. Tomiyama, Y.Higashi, B. Takase et al., "Relationships among hyperuricemia,metabolic syndrome, and endothelial function," American Journal of Hypertension, vol. 24, no. 7, pp. 770-774, 2011.
17. S. Zharikov, K. Krotova, H. Hu et al., "Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells," American Journal of Physiology-Cell Physiology, vol. 295, no. 5, pp. C1183-C1190, 2008.
18. D.-H. Kang, S.-K. Park, I.-K. Lee, and R. J. Johnson, "Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells," Journal of the American Society of Nephrology, vol. 16, no. 12, pp. 3553-3562, 2005.
19. L. G. Sánchez-Lozada, E. Tapia, R. López-Molina et al., "Effects of acute and chronic L-arginine treatment in experimental hyperuricemia," American Journal of Physiology-Renal Physiology, vol. 292, no. 4, pp. F1238-F1244, 2007.
20. M. A.Gonzalez andA. P. Selwyn, "Endothelial function, inflammation, and prognosis in cardiovascular disease," American Journal of Medicine, vol. 115, supplement 8, pp. 99S-106S, 2003.
21. Y.Higashi, K.Noma,M. Yoshizumi, and Y. Kihara, "Endothelial function and oxidative stress in cardiovascular diseases," Circulation Journal, vol. 73, no. 3, pp. 411-418, 2009.
22. R. H. Böger, "Association of asymmetric dimethylarginine and endothelial dysfunction," Clinical Chemistry and Laboratory Medicine, vol. 41, pp. 1467-1472, 2003.
23. I. Palomo, A. Contreras, L. M. Alarcón et al., "Elevated concentration of asymmetric dimethylarginine (ADMA)in individuals with metabolic syndrome," Nitric Oxide, vol. 24, no. 4, pp. 224-228, 2011.
24. C. Korandji, M. Zeller, J. C. Guilland et al., "Time course of asymmetric dimethylarginine (ADMA) and oxidative stress in fructose-hypertensive rats: A model related to metabolic syndrome," Atherosclerosis, vol. 214, no. 2, pp. 310-315, 2011.
25. A. Surdacki, M. Nowicki, J. Sandmann et al., "Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension," Journal of Cardiovascular Pharmacology, vol. 33, no. 4, pp. 652-658, 1999.
26. R. H. Böger, S. M. Bode-Böger, A. Szuba et al., "Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia," Circulation, vol. 98, no. 18, pp. 1842-1847, 1998.
27. J. Sladowska-Kozlowska, M. Litwin, A.Niemirska et al., "Oxidative stress in hypertensive children before and after 1 year of antihypertensive therapy," Pediatric Nephrology, vol. 27, no. 10, pp. 1943-1951, 2012.
28. I. Kanazawa, S. Yano, Y. Notsu, T. Yamaguchi, T. Nabika, and T. Sugimoto, "Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus," Clinical Endocrinology, vol. 74, no. 4, pp. 467-472, 2011.
29. K. Krzyzanowska, F. Mittermayer, H.-P. Kopp, M. Wolzt, and G. Schernthaner, "Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women," Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 12, pp. 6277-6281, 2004.
30. A.Wasilewska, E. Tenderenda, K. Taranta-Janusz, J. Tobolczyk, and J. Stypułkowska, "Markers of systemic inflammation in children with hyperuricemia," Acta Paediatrica, International Journal of Paediatrics, vol. 101, no. 5, pp. 497-500, 2012.
31. A. Tojo, W. J. Welch, V. Bremer et al., "Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney," Kidney International, vol. 52, no. 6, pp. 1593-1601, 1997.
32. E. Schepers, D. V. Barreto, S. Liabeuf et al., "Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease," Clinical Journal of the American Society of Nephrology, vol. 6, no. 10, pp. 2374-2383, 2011.
33. A. Meinitzer, J. T. Kielstein, S. Pilz et al., "Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the ludwigshafen risk and cardiovascular health study," Clinical Chemistry, vol. 57, no. 1, pp. 112-121, 2011.
34. F. Schulze, A. M. Carter, E. Schwedhelm et al., "Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke," Atherosclerosis, vol. 208, no. 2, pp. 518-523, 2010.
35. C. Zoccali, S. M. Bode-Böger, F. Mallamaci et al., "Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study," The Lancet, vol. 358, no. 9299, pp. 2113-2117, 2001.
36. C. Fleck, F. Schweitzer, E. Karge, M. Busch, and G. Stein, "Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases," Clinica Chimica Acta, vol. 336, no. 1-2, pp. 1-12, 2003.